GAMMA Investing LLC Invests $44,000 in Galapagos NV (NASDAQ:GLPG)

GAMMA Investing LLC acquired a new stake in Galapagos NV (NASDAQ:GLPG) in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm acquired 1,161 shares of the biotechnology company’s stock, valued at approximately $44,000.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Acadian Asset Management LLC increased its position in shares of Galapagos by 173.8% in the third quarter. Acadian Asset Management LLC now owns 19,149 shares of the biotechnology company’s stock valued at $661,000 after buying an additional 12,154 shares in the last quarter. FMR LLC raised its position in Galapagos by 0.7% during the third quarter. FMR LLC now owns 4,317,676 shares of the biotechnology company’s stock worth $149,176,000 after acquiring an additional 28,497 shares during the last quarter. China Universal Asset Management Co. Ltd. lifted its holdings in shares of Galapagos by 357.6% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 2,265 shares of the biotechnology company’s stock valued at $92,000 after purchasing an additional 1,770 shares in the last quarter. Citigroup Inc. grew its position in shares of Galapagos by 7,243.0% in the third quarter. Citigroup Inc. now owns 90,686 shares of the biotechnology company’s stock valued at $3,133,000 after purchasing an additional 89,451 shares during the last quarter. Finally, Hudson Bay Capital Management LP grew its position in shares of Galapagos by 7.7% in the third quarter. Hudson Bay Capital Management LP now owns 350,000 shares of the biotechnology company’s stock valued at $12,092,000 after purchasing an additional 25,000 shares during the last quarter. 32.46% of the stock is owned by institutional investors and hedge funds.

Galapagos Stock Down 1.2 %

GLPG stock opened at $29.09 on Friday. The stock has a market capitalization of $1.92 billion, a price-to-earnings ratio of -12.70 and a beta of 0.27. The stock’s fifty day simple moving average is $32.11 and its 200-day simple moving average is $36.00. Galapagos NV has a 52-week low of $28.30 and a 52-week high of $45.21.

Analyst Ratings Changes

A number of research firms recently issued reports on GLPG. Morgan Stanley reaffirmed an “equal weight” rating and issued a $38.00 target price on shares of Galapagos in a research note on Monday, April 22nd. Bank of America restated an “underperform” rating and issued a $31.00 price objective (down from $41.00) on shares of Galapagos in a research report on Thursday, March 28th. Finally, StockNews.com cut Galapagos from a “buy” rating to a “hold” rating in a research report on Monday, March 18th. One research analyst has rated the stock with a sell rating, four have issued a hold rating and one has assigned a buy rating to the stock. According to MarketBeat, the stock currently has an average rating of “Hold” and a consensus target price of $34.50.

About Galapagos

Galapagos NV, a biotechnology company, develops medicines focusing on oncology and immunology primarily in the United States and Europe. The company's pipeline products comprise GLPG3667 that has completed phase 1b trial; GLPG5101, a CD19 CAR-T product candidate manufactured at point-of-care, currently in Phase1/2 trial in relapsed/refractory non-hodgkin lymphoma; GLPG5201, a CD19 CAR-T product candidates manufactured at point-of-care, currently in phase 1/2 trial in replapsed/refractory chronic lymphocytic leukemia; and GLPG5301, a BCMA CAR-T product candidate manufactured at point-of-care, currently in phase 1/2 in relapsed/refractory multiple myeloma.